Results 131 to 140 of about 164,625 (307)

lymphoblast

Citation: 'lymphoblast' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.13398 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.
openaire   +1 more source

Investigating the role of BCL-xL IN T-cell acute lymphoblastic leukemia

Each year in the United States, around 6540 people between the ages of 1 and 19 are diagnosed with Acute Lymphoblastic Leukemia (ALL). ALL is comprised of subtypes, which include B-cell acute lymphoblastic leukemia (B-ALL) and T-cell acute lymphoblastic ...
Agyei, Emmanuel Yaw
core  

Results of chemotherapy by UKCCSG protocol in children with acute lymphoblastic leukemia: Clinical characteristics and outcome [PDF]

Background: Acute lymphoblastic leukemia (ALL) represents a clonal expansion and arrest of normal lymphoid hematopoiesis. ALL remains the most common malignancy in children.
پدرام, محمد, فتحی, افشین, هیرادفر, امیر عطا ا...   +2 more
core  

Acute Lymphoblastic Leukemia and Seizures

, 1995
The incidence, timing, etiologies, and recurrence rate of seizures among 127 pediatric patients with acute lymphoblastic leukemia (ALL) were determined at the Schneider Children’s Hospital, and the Long Island Jewish Medical Center, New ...
J Gordon Millichap, Millichap, J. Gordon
core   +1 more source

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

British Journal of Haematology, EarlyView.
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz, Rémi Letestu, Mary Sartor, Stephen Mulligan, Marie C. Béné, Gavin Cull, Dennis Carney, William Renwick, Andrew Grigg, Cecily Forsyth, Gregory Hapgood, Emma Verner, Rosemary Harrup, Pauline Warburton, Kylie Mason, Richard Eek, Wojciech Janowski, Jean Pierre Vilque, Maya Latimer, Laurent Voillat, Sophie De Guibert, Bernard Drenou, Robert Blum, Caroline Dartigeas, Lachlan Hayes, Nicolas Daguindau, Mourad Tiab, Véronique Leblond, Andrew Shearer, Masa Lasica, Pierre Morel, Bohrane Slama, Anne Banos, Annie Brion, Emmanuelle Ferrant, Jessica Michel, Cécile Tomowiak, Edward Morris, Hanlon Sia, Kelly Kratzing, Belinda E. Butcher, Abdelmalek Dahmani, Stephen Robert Larsen, Piers Blombery, Florence Cymbalista, David J. Gottlieb   +45 more
wiley   +1 more source

[Malignant myelofibrosis. Evolution toward acute lymphoblastic leukemia]

, 1982
To report a case of malignant myelofibrosis evolved toward acute lymphoblastic ...
Fantesini, C, Prandi, S, SALVARANI, CARLO, Iori, I   +3 more
core  

The leukaemia in pregnancy study, a national multicentre retrospective study of pregnancy outcomes in women with concurrent or historic diagnoses of acute leukaemia

British Journal of Haematology, EarlyView.
Summary The leukaemia in pregnancy study was a multicentre retrospective study of pregnancy outcomes of women with concurrent (CAL) or previous (PAL) acute leukaemia. Cases were identified from eight hospitals. Of 39 screened cases, 12 CAL and 21 PAL cases were described, with one belonging to both groups.
Lukas Pitel, Matthew Northgraves, Judith Cohen, Chao Huang, John Turgoose, Simone Green, Steve Knapper, Gail Jones, Sarah Essex, Julie Kenny, Mhairi Copland, Panagiotis D. Kottaridis, Anjum Khan, Sahra Ali, David Allsup   +14 more
wiley   +1 more source

Lymphoblastic Erythrodermia [PDF]

Proceedings of the Royal Society of Medicine, 1927
openaire   +2 more sources

Patient‐specific genomic measurable residual disease markers for monitoring acute myeloid leukaemia and myeloid malignancy

British Journal of Haematology, EarlyView.
Standardised DNA based measurable residual disease (MRD) monitoring is possible for acute myeloid leukaemia (AML) and myeloid malignancy patients. Targeted next‐generation sequencing (NGS) and RNA‐seq permit marker development for clinically identified lesions and whole genome sequencing (WGS) permits MRD marker development in patients without ...
Libby Huang, Louise Doculara, Luis Enriquez, Jodie Giles, Umma Habiba, Anita Y. Bahar, Tammy Law, Weronika Lesnowolska, Hannah McCalmont, Erika Ong, Laura Piras, Benjamin Schreiber, Nicola Venn, Wiebke Wessels, Yianni Bletas, Minjina Kang, Sam Yuen, Patrick Strong, Paulette Barahona, Ann‐Kristin Altekoester, Kimberly Dias, Dianne Sylvester, Marie Erasmus Wong, Renee Eslick, Luciano Dalla Pozza, Bhavna Padhye, Ashanka Beligaswatte, Chow Yee Lai, Michelle Ng, Chris Fraser, David Hughes, Seong Lin Khaw, Karen McCleary, Sophie Jessop, Manika Pal, Lucie Winkowska, Jan Zuna, Patrizia Larghero, Rolf Marschalek, Claus Meyer, Rishi S. Kotecha, Andrew S. Moore, Mark J. Cowley, Rosemary Sutton, Michelle J. Henderson, Toby N. Trahair   +45 more
wiley   +1 more source

Prospective phase I study of nivolumab to promote graft‐versus‐tumour in relapsed or refractory haematological malignancy post allogeneic haematopoietic stem cell transplantation

British Journal of Haematology, EarlyView.
Baseline immunophenotype and gene expression predict suitability for salvage nivolumab in patients with relapsed/refractory haematological malignancy. Summary Allogeneic haematopoietic stem cell transplantation (alloHSCT) relies on donor‐derived T cells to mediate the graft‐versus‐tumour (GVT) effect, but relapse may result from impaired immune ...
Trung Q. Ngo, Eric Wong, Joanne E. Davis, Mandy Ludford‐Menting, Jessica Klass, Sara K. Dohrmann, Rachel Koldej, David Ritchie   +7 more
wiley   +1 more source